This patent teaches that by manipulating divalent ion content of a tissue culture media, it is possible to modify the differentiation program of neuronal stem cells. Various methods of inducing differentiation of such neuronal stem cells into neurons, astrocytes, and oligodendrocytes are disclosed.
This patent covers the inhibition of hematopoietic stem cell differentiation through administration of the protein called "delta-like protein" (dlk). The patent teaches not only the use for expansion, but also for protecting the stem cell compartment from the effects of chemotherapy or radiotherapy.
Parathyroid hormone is a polypeptide secreted by the parathyroid gland in order to regulate calcium concentrations in the blood. Low calcium levels stimulate secretion of parathyroid hormone which in turn activates osteoclasts to release calcium deposits from bone.
The use of parathyroid hormone to modulate stem cells has been demonstrated clinically by Ballen et al who showed that
This patent covers the use of anti-MHC antibodies to induce "retrodifferentiation" of peripheral blood cells into CD34 hematopoietic stem cells. If there is even a shred of evidence that the concepts put forth in this patent are real, then the inventors are sitting on a gold mine. However, with exception to publications in very very low impact journals only by...
This patent teaches how to induce differentiation of mesenchymal stem cells into chondrocytes. The tissue culture conditions described may be used for generation of artificial cartilage. This patent is useful in combination with the numerous patents that describe three dimensional matrices and scaffolds useful for making cartilage.
This patent covers the use of the retinoid receptor pathway to induce differentiation of adipocyte stem cells in vivo and therefore make a patient who is insulin resistant, insulinn sensitive.
This patent covers composition of matter on a factor, which seems to be not clearly stated, that can induce both proliferation and differentiation of hematopoietic stem cells, as well as stem cells that have been committed to the lymphoid lineage. This patent is particularly useful for treatment of patients after bone marrow transplantation, or chemotherapy, or radiation therapy.
This patent teaches how to generate T cells from hematopoietic stem cells in vitro. T cells may be used for immune stimulation, or in some other cases may be used for generation of T suppressor cells. If nuclear transfer can be performed in the starting population of cells, then patient-specific T cells may be generated.
Disclosed are tissue culture conditions that can direct the differentiation of mesenchymal stem cells into the following cell lineages: osteogenic, chondrogenic, tendonogenic, ligamentogenic, myogenic, marrow stromagenic, adipogenic and dermogenic. This patent is useful for the generation of artificial tissue. Although the mesenchymal stem cells themselves are poorly immunogenic, the...
This patent teaches ways of inducing the differentiation of mesenchymal stem cells into bone, cartilage and other non-hematopoietic tissues.